GlobeNewswire by notified

Biotalys to Participate in Upcoming Investor and Stakeholder Events

Share

Ghent, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Press release

Biotalysto Participate in Upcoming Investor and Stakeholder Events

Ghent, BELGIUM – 21September2021 Biotalys (Euronext - BTLS), an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, today announces that it will be presenting at the following events during the remainder of 2021:

Bryan-Garnier Food Tech Virtual Conference, 23-24 September
CEO Patrice Sellès and CFO Wim Ottevaere will be speaking at Bryan Garnier & Co.’s Food Tech Conference on Friday 24 September at 15:00 CEST to an international audience of investors, with a presentation and Q&A session.

Knowledge for Growth (FlandersBio), 28 September
Biotalys will give a company presentation and participate in a panel debate on Europe’s Farm to Fork strategy at Knowledge for Growth on Tuesday 28 September 2021, at 14:00 CEST. The conference takes place in Ghent and is attended by decision makers from the biotech, pharma and medtech, agricultural and chemical industries as well as investors, universities and research institutes.

VIB 25 Year Anniversary, 13 October
Biotalys will feature as one of the key spinoffs at the event in Brussels for the 25th anniversary of VIB, the Flemish Institute for Biotechnology.

CongresoRedagrícola Biocontrol, 13-15 October
Carlos Reyes, Field Prodcut Development Manager at Biotalys, will be giving a talk in this online conference. The Latin America-based event will span over three days, with workshops, roundtables and keynote lectures.

VFBHappening 2021, 23 October
Wim Ottevaere, CFO, and Toon Musschoot, Head IR & Communication, will represent Biotalys in a booth at this retail investor conference in Kinepolis, Antwerp.

Food Tech Congress, 3-4 November
CEO Patrice Sellès will speak at the AgriTech session during this year's FoodTech Congress on Thursday 4 November 2021.

Kepler Cheuvreux’s Global Agri Forum, 15 November
Biotalys' CEO, Patrice Sellès, and CFO, Wim Ottevaere, will speak with investors at this year's Global Agri Forum organised by Kepler Cheuvreux (virtual format).

DeutschesEigenkapitalforum, 22-24 November
Biotalys' management will give a company presentation at the Deutsches Eigenkapitalforum (EKF) on Wednesday 24 November 2021 at 14:00 CEST (virtual format).

KBCSecurities Small & Mid Cap Conference, 9-10 December
Biotalys will participate in this event for institutional investors in Brussels. CEO, Patrice Sellès, CFO, Wim Ottevaere and Toon Musschoot, Head IR & Communication, will represent the company.        

-ENDS -

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since 2 July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Head of Investor Relations & Communications
T: +32 (0)9 274 54 00
E: Toon.Musschoot@biotalys.com

Consilium Strategic Communications
Amber Fennell
T: +44 (0)203 709 5700
E: Biotalys@consilium-comms.com

Important Notice

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

DSV, 1103 - INTERIM FINANCIAL REPORT Q1 202424.4.2024 07:30:53 CEST | Press release

Company Announcement No. 1103 Selected key figures and ratios for the period 1 January – 31 March 2024 Q1 2024Q1 2023Key figures (DKKm)Revenue38,34040,954Gross profit10,26511,391Operating profit (EBIT) before special items3,6414,672Profit for the period2,3933,287Adjusted earnings for the period2,4633,340RatiosConversion ratio35.5%41.0%Diluted adjusted earnings per share of DKK 1 for the last 12 months55.376.9 Jens H. Lund, Group CEO: “In a normalising market, we are off to a good start delivering strong financial results in the first quarter of 2024, and I am particularly satisfied that we are gaining market shares in all three divisions. We have also completed the leadership changes, the organisation has settled, and together with the new and experienced leadership team we will concentrate our efforts on executing on our strategy, with particular focus on our customers.” Outlook for 2024 We maintain our outlook for 2024 as announced in the 2023 Annual Report: Operating profit (EBIT) b

Ringkjøbing Landbobanks kvartalsrapport for 1. kvartal 202424.4.2024 07:30:00 CEST | pressemeddelelse

Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter 24. april 2024 Ringkjøbing Landbobanks kvartalsrapport for 1. kvartal 2024 Bankens bestyrelse og direktion har i dag godkendt kvartalsrapporten for 1. kvartal 2024. Banken realiserer i årets første kvartal et basisresultat på 793 mio. kroner og et resultat efter skat på 616 mio. kroner. Resultatet efter skat forrenter egenkapitalen med 24% p.a. Basisresultat (mio. kroner)1. kvartal 20241. kvartal 20232023202220212020Basisindtjening i alt1.0408493.8282.8622.4332.179Samlede udgifter og afskrivninger247227963891817788Basisresultat før nedskrivninger på udlån7936222.8651.9711.6161.391Nedskrivninger på udlån m.v.0-1-1-2-68-223Basisresultat7936212.8641.9691.5481.168Beholdningsresultat m.v.+23-21-7-69+7-9Af- og nedskrivninger på immaterielle aktiver5520201715Skat195140682385309224Resultat efter skat6164552.1551.4951.229920 1. kvartal 2024 i overskrifter Resultatet efter skat udgør 616 mio. kroner, hvilket forrenter e

Ringkjøbing Landbobank’s quarterly report for the first quarter of 202424.4.2024 07:30:00 CEST | Press release

Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders 24 April 2024 Ringkjøbing Landbobank’s quarterly report for the first quarter of 2024 The bank’s board of directors and general management today approved the quarterly report for the first quarter of 2024. The bank delivers core earnings of DKK 793 million and net profit of DKK 616 million in the first quarter of the year. The net profit is equivalent to a 24% p.a. return on equity. Core earnings (DKK million)Q1 2024Q1 20232023202220212020Total core income1,0408493,8282,8622,4332,179Total expenses and depreciation247227963891817788Core earnings before impairment charges for loans7936222,8651,9711,6161,391Impairment charges for loans etc.0-1-1-2-68-223Core earnings7936212,8641,9691,5481,168Result for the portfolio etc.+23-21-7-69+7-9Amortisation and write-downs on intangible assets5520201715Tax195140682385309224Net profit6164552,1551,4951,229920 Highlights of the first quarter of 2024 The net profit is DKK 616 mi

Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release

Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release

Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem

HiddenA line styled icon from Orion Icon Library.Eye